Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

[EX Q]: The United States Exploring Expedition was an exploring and surveying expedition of the Pacific Ocean and surrounding lands conducted by the United States from 1838 to 1842.
[EX A]: On what date did United States Exploring Expedition end?

[EX Q]: Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro. We evaluated the safety, pharmacokinetics, immunogenicity, and antitumor effect of siltuximab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. This open-label, phase 1, dose-escalating study used two doses of siltuximab: 5.5 and 11.0 mg/kg (administered on day 1 of each 21-day cycle). In total, nine patients were treated. The most common grade 3/4 adverse events, lymphopenia (89 %) and thrombocytopenia (44 %), occurred in patients receiving both doses of siltuximab; however, no dose-limiting toxicities (DLTs) were observed. Following intravenous administration of siltuximab at 5.5 and 11.0 mg/kg, the maximum serum concentration and the area under the curve from 0 to 21 days and from 0 to infinity increased in an approximately dose-proportional manner. Mean half-life, total systemic clearance, and volume of distribution were similar at doses of 5.5 and 11.0 mg/kg. Across both doses, six of the nine patients had complete or partial response (22 and 44 %, respectively). In conclusion, as no DLT was observed, the recommended dose for this combination is 11.0 mg/kg once every 3 weeks. The study is registered at [Link] as NCT01309412.
[EX A]: Which interleukin is blocked by Siltuximab?

[EX Q]: TGF-1 regulates bone metabolism and mediates bone turnover during postmenopause. Sclerostin negatively regulates Wnt signaling pathway and also has an important role in postmenopausal bone loss. Little is known about the relationship between serum TGF-1 and sclerostin during menopause. We compared serum levels of TGF-1 and sclerostin in pre- and postmenopausal women and assessed the potential correlations of these levels with each other and with serum levels of bone turnover markers and bone mineral density. A total of 176 women (58 premenopausal, 62 early postmenopausal, and 56 late postmenopausal) were included in this study. Serum TGF-1 level was significantly higher in early postmenopausal women compared with premenopausal (32.07.19 vs. 26.556.67 ng/ml, p=0.01) and late postmenopausal (32.07.19 vs. 28.657.70 pg/ml, p=0.031) women, and no significant differences in serum sclerostin levels were observed among the 3 groups. There was a significant negative correlation between TGF-1 and sclerostin in early postmenopausal women, but not in other groups of women. Based on multiple regression analysis, only TGF-1 (=-0.362; p=0.007) was an independent predictor of sclerostin during early postmenopause. Our findings suggest that serum TGF-1 level increases during postmenopause and declines in old age. Sclerostin production is inhibited by TGF-1 during early postmenopause.
[EX A]:
Sclerostin regulates what process?